Background
==========

Diabetes mellitus leads to the development of retinopathy, which is the main cause of vision loss in young adults in developed countries \[[@b1-medscimonit-20-2729]\]. According to the World Health Organization (WHO), diabetic retinopathy (DR) accounts for approximately 5% of global blindness \[[@b2-medscimonit-20-2729]\]. DR is characterized by gradually progressive alterations in the retinal microvasculature, leading to areas of retinal non-perfusion, increased vasopermeability, and, in response to retinal nonperfusion, pathologic intraocular proliferation of retinal vessels \[[@b3-medscimonit-20-2729]\]. It is believed that the main etiologic mechanisms of DR are hypoxia-induced inflammation and angiogenesis \[[@b4-medscimonit-20-2729]\].

Visfatin, a highly conserved 52-kDa protein, is a novel adipokine. Visfatin was originally cloned from human peripheral blood lymphocytes and characterized as nicotinamide phosphoribosyltransferase (Nampt), an enzyme that synthesizes nicotinamide mononucleotide from nicotinamide \[[@b5-medscimonit-20-2729]\]. Visfatin is involved in the regulation of glucose homeostasis by exerting a hypoglycemic effect through the reduction of glucose release from hepatocytes and the stimulation of glucose utilization in peripheral tissues \[[@b6-medscimonit-20-2729]\]. A recent study showed that visfatin exerted angiogenic effects on human umbilical vein endothelial cells through the mammalian target of rapamycin (mTOR) signaling pathway \[[@b7-medscimonit-20-2729]\]. Therefore, it is hypothesized that visfatin may be involved in the pathogenesis of DR.

Although studies have focused on the relation of serum visfatin with diabetes \[[@b8-medscimonit-20-2729]\], no investigation on the association of serum visfatin and DR has been performed. We aimed to determine serum and vitreous levels of visfatin in patients with DR to assess the role of visfatin in DR.

Material and Methods
====================

Patients
--------

We enrolled 280 diabetic patients \[124 patients without DR, 56 with non-PDR (NPDR), and 100 with PDR\] undergoing vitreoretinal surgery. Serum was obtained from all the participants and vitreous samples were drawn from the diabetic patients at the time of surgery. Exclusion criteria were chronic disease (other than diabetes), allergy, neoplasm, previous vitrectomy, photocoagulation, and intra-vitreal hemorrhages during the 3 months preceding the study. The control group consisted of 78 patients who had undergone vitrectomy for the treatment of retinal detachment (RD) with no proliferative vitreoretinopathy. Controls were free from systemic disease. This study was approved by the research ethics committee of our hospital and was conducted in agreement with the Declaration of Helsinki. Written informed consent was obtained from the patients and healthy volunteers prior to their participation in this study.

Measurements
------------

Serum was obtained from blood samples by centrifugation and stored at −80°C until analysis. Vitreous samples were collected undiluted by manual suction to a syringe through the aspiration line of vitrectomy, before opening the infusion line. Vitreous samples were transferred on ice, centrifuged, and supernatants were stored at −80°C until analysis. The serum and vitreous samples were analyzed for visfatin using a commercially available ELISA (R&D Systems Inc., Minneapolis, MN, USA).

Statistical analysis
--------------------

Data are presented as means ±SD or median (interquartile range). Data normality was analyzed using the Kolmogorov-Smirnov test. The differences in characteristics between patients with PDR and NPDR, diabetic patients without DR, and control subjects were compared using chi-square tests, one-way ANOVA, or Kruskal-Wallis test. Statistical analysis was carried out using SPSS version 13.0 software program (SPSS Inc, Chicago, Illinois). All analyses reported significance at the *P*\<0.05 level.

Results
=======

Baseline clinical characteristics
---------------------------------

The clinical characteristics of diabetic patients and control subjects are presented in [Table 1](#t1-medscimonit-20-2729){ref-type="table"}. Increased levels of systolic blood pressure (SBP), diastolic blood pressure (DBP), HbA1c, fasting plasma glucose (FPG), 2-h postprandial plasma glucose (P~2h~PG), and triglycerides (TG) were found in the diabetic group compared with healthy controls. The levels of HDL-C were significantly elevated in NPDR and PDR patients compared with controls. Furthermore, diabetic patients without DR had relatively higher low-density lipoprotein cholesterol (LDL-C) levels than the other 3 groups.

Serum and vitreous visfatin levels between the three groups
-----------------------------------------------------------

Serum and vitreous visfatin levels in controls, diabetic patients without DR, NPDR patients, and PDR patients are shown in [Table 2](#t2-medscimonit-20-2729){ref-type="table"}. Serum and vitreous visfatin levels in PDR patients were significantly elevated compared with those in the other 3 groups. Control subjects had significantly lower levels of serum and vitreous visfatin compared with diabetic patients without DR, NPDR patients, and PDR patients. In addition, NPDR patients showed elevated vitreous visfatin levels compared with patients without DR. However, no significant differences in serum visfatin levels were found between NPDR patients and patients without DR.

Discussion
==========

This study provides the first report of the association of serum and vitreous visfatin levels with the presence and severity of DR. The results indicate that serum and vitreous visfatin levels in PDR patients were significantly elevated compared with those in control subjects, diabetic patients without DR, and NPDR patients. NPDR patients showed elevated vitreous visfatin levels compared to patients without DR.

Visfatin exerted insulin-mimetic effects in cultured cells and lowered plasma glucose levels by binding to and activating the insulin receptor in mice. Mice heterozygous for a targeted mutation in the visfatin gene had modestly higher levels of plasma glucose relative to wild-type littermates \[[@b8-medscimonit-20-2729]\]. Visfatin has been shown to be associated with the development of diabetes. Serum visfatin levels were found to be elevated in patients with type 2 diabetes \[[@b8-medscimonit-20-2729]\], type 1 diabetes \[[@b9-medscimonit-20-2729]\], and gestational diabetes mellitus \[[@b10-medscimonit-20-2729]\]. In addition, a polymorphism in the promoter of visfatin is associated with the presence of type 2 diabetes. All these results point to the role of visfatin in the mechanism of diabetes.

Adipose tissue is no longer considered to be an inactive organ that only stores lipids and serves as an energy reservoir. Numerous studies have shown that it is an active endocrine organ and secretes many substances called adipokines, including tumor necrosis factor α (TNF-α), adiponectin, leptin, resistin, and apelin, which are involved in the regulation of several metabolic and physiologic processes \[[@b11-medscimonit-20-2729]\]. Serum and vitreous levels of several adipokines such as leptin, resistin, and apelin were found to be higher in patients with PDR compared with controls \[[@b12-medscimonit-20-2729]--[@b14-medscimonit-20-2729]\]. On the other hand, serum adiponectin concentrations in patients with PDR or NPDR were significantly lower than those in patients without diabetic retinopathy \[[@b15-medscimonit-20-2729]\], indicating that adipokines play an important role in the pathogenesis of DR. Our results showed that serum and vitreous visfatin levels were significantly elevated in patients with PDR and NPDR compared with controls. PDR patients showed significantly higher levels of serum and vitreous visfatin compared with NPDR patients. This suggests that serum and vitreous visfatin may serve as a biomarker to predict the presence and severity of DR in order to evaluate the risk of developing DR in diabetic patients and then to target strategies to prevent DR for patients with diabetes.

Angiogenesis, the process by which new vascular networks develop from preexisting vessels, is a traditional characteristic of PDR and often leads to catastrophic loss of vision due to vitreous hemorrhage and/or traction retinal detachment. Angiogenesis is regulated by a dynamic balance between angiogenic stimulators and inhibitors \[[@b16-medscimonit-20-2729]\]. A recent study showed that visfatin potently stimulates neovascularization in chick chorioallantoic membrane and mouse Matrigel plug \[[@b17-medscimonit-20-2729]\]. It also activates migration, invasion, and tube formation in human umbilical vein endothelial cells (HUVECs) \[[@b17-medscimonit-20-2729]\]. Moreover, visfatin evokes activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) in endothelial cells, which is closely linked to angiogenesis \[[@b17-medscimonit-20-2729]\]. In another study, visfatin was found to concentration- and time-dependently enhance cell migration and tube formation, indicating the angiogenic capability of HUVECs via regulating VEGF, which is an important regulator for the angiogenesis of DR \[[@b18-medscimonit-20-2729]\]. Therefore, visfatin may be involved in the pathogenesis of DR by promoting the angiogenesis process.

This study has several potential limitations. First, the sample size was not large enough to reach definitive conclusions. Further studies with larger numbers of subjects are warranted. Second, our study had a cross-sectional design and the causative relationship must be confirmed by longitudinal studies.

Conclusions
===========

Serum and vitreous visfatin levels were correlated with the presence and severity of DR. Serum and vitreous visfatin levels may serve as new biomarkers in addition to the traditional methods for assessing the risk of DR.

**Source of support:** Departmental sources

###### 

Clinical and biochemical characteristics of diabetic patients and controls.

                     Controls       Diabetic patients                                                  *P*                                                                                                                                                                                       
  ------------------ -------------- ------------------------------------------------------------------ ------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------- ---------
  N                  78             124                                                                56                                                                 100                                                                                                                    
  Age (years)        56.72±7.68     55.98±10.27                                                        54.75±10.27                                                        56.03±11.10                                                                                                            0.737
  Gender (M/F)       40/38          54/70                                                              27/29                                                              49/51                                                                                                                  0.497
  BMI (Kg/m^2^)      25.45±1.83     25.20±3.78                                                         25.37±3.23                                                         25.98±3.87                                                                                                             0.386
  SBP (mmHg)         123.04±12.03   142.86±27.65[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}   144.91±27.16[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}   145.50±29.01[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}                                                       \<0.001
  DBP (mmHg)         77.71±7.56     85.97±14.02[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}    85.27±15.62[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}    85.06±17.01[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}                                                        \<0.001
  HbA1c (%)          5.04±0.72      9.05±2.26[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}      8.88±2.51[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}      9.20±2.34[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}                                                          \<0.001
  FPG (mmol/L)       5.10±0.37      7.56±2.37[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}      7.36±2.10[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}      7.87±2.78[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}                                                          \<0.001
  P~2h~PG (mmol/L)   5.92±0.66      16.96±4.08[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}     16.20±3.52[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}     16.99±3.90[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}                                                         \<0.001
  TC (mmol/L)        5.07±0.88      5.20±1.31                                                          5.14±1.03[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}      5.18±1.22                                                                                                              0.886
  TG (mmol/L)        1.12±0.31      1.96±0.48[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}      1.93±0.45[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}      1.98±0.42[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}                                                          \<0.001
  LDL-C (mmol/L)     3.24±0.73      3.34±1.05                                                          3.42±0.83[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}      3.41±1.06                                                                                                              0.640
  HDL-C (mmol/L)     1.45±0.27      1.37±0.31                                                          1.12±0.18[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"}      1.22±0.35[\*](#tfn1-medscimonit-20-2729){ref-type="table-fn"},[\*\*](#tfn2-medscimonit-20-2729){ref-type="table-fn"}   \<0.001

*P*\<0.05 *vs.* control;

*P*\<0.05 *vs.* diabetic patients without DR.

###### 

Serum and vitreous visfatin levels in controls, diabetic patients without DR, NPDR patients, and PDR patients.

  Visfatin (ng/mL)   Controls (n=78)                                                                                                                       Without DR (n=124)                                                         NPDR (n=56)                                                                                                                       PDR (n=100)                                                                                                                                                                                *P* value
  ------------------ ------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -----------
  Serum              23.17 (18.63--27.78)[\*\*](#tfn4-medscimonit-20-2729){ref-type="table-fn"},[\*\*\*](#tfn5-medscimonit-20-2729){ref-type="table-fn"}   28.76 (22.68--33.83)[\*](#tfn3-medscimonit-20-2729){ref-type="table-fn"}   30.85 (23.98--34.19)[\*](#tfn3-medscimonit-20-2729){ref-type="table-fn"}                                                          34.59 (29.68--38.56)[\*](#tfn3-medscimonit-20-2729){ref-type="table-fn"},[\*\*](#tfn4-medscimonit-20-2729){ref-type="table-fn"},[\*\*\*](#tfn5-medscimonit-20-2729){ref-type="table-fn"}   \<0.001
  Vitreous           12.72 (10.20--15.24)[\*\*](#tfn4-medscimonit-20-2729){ref-type="table-fn"},[\*\*\*](#tfn5-medscimonit-20-2729){ref-type="table-fn"}   16.60 (14.48--19.79)[\*](#tfn3-medscimonit-20-2729){ref-type="table-fn"}   18.91 (15.69--21.66)[\*](#tfn3-medscimonit-20-2729){ref-type="table-fn"},[\*\*](#tfn4-medscimonit-20-2729){ref-type="table-fn"}   21.35 (16.74--23.41)[\*](#tfn3-medscimonit-20-2729){ref-type="table-fn"},[\*\*](#tfn4-medscimonit-20-2729){ref-type="table-fn"},[\*\*\*](#tfn5-medscimonit-20-2729){ref-type="table-fn"}   \<0.001

*P*\<0.05 *vs.* control;

*P*\<0.05 *vs.* diabetic patients without DR;

*P*\<0.05 *vs.* NPDR patients.
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